

# SU11274

Catalog No: tcsc0144



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

658084-23-2

**Formula:**

$C_{28}H_{30}ClN_5O_4S$

**Pathway:**

Protein Tyrosine Kinase/RTK;Autophagy

**Target:**

c-Met/HGFR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

PKI-SU11274

**Observed Molecular Weight:**


568.09

## Product Description

SU11274 is a selective **Met** inhibitor with **IC<sub>50</sub>** of 10 nM, but has no effects on PGDFR $\beta$ , EGFR or Tie2.

IC50 & Target: IC50: 10 nM (Met)<sup>[1]</sup>

**In Vitro:** SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3 $\beta$ . SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC<sub>50</sub> of 50 of 1-1.5  $\mu$ M. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC<sub>50</sub> of 3.4  $\mu$ M and 6.5  $\mu$ M, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5  $\mu$ M, and induces caspase-dependent apoptosis by 24% at 1  $\mu$ M<sup>[2]</sup>. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC<sub>50</sub> values of 0.8-4.4  $\mu$ M, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!